The brief
- Chai-2 designs full-length antibodies with 16–20% hit rates across 52 clinical targets, ~100x improvement over prior methods.
- July 2026 Series C of $400M at $3.8B valuation accelerates commercial deployment with major pharma partners.
- Bypasses traditional phage display, replacing months of lab work with days of computation.
Technical approach
Zero-shot design
Predicting antibodies without templates
Chai-2 learns rules of antibody architecture and generates novel designs optimized for targets in one shot.
Diverse targets
Generalizing across biology
The model trains on natural antibody diversity and learns binding principles, enabling design for new targets with no prior data.
Full-length design
Complete protein sequences
Designs entire antibody sequences including variable and constant regions, enabling direct synthesis and expression.
